FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2593289896> ?p ?o ?g. }

• W2593289896 abstract "Introduction The PiA-study (Prognostic assessment in routine Application, NCT 01592825) was designed as a representative cohort of breast cancer patients to estimate the proportions of traditional and modern prognostic factors. The ASCO-recommended biomarkers uPA (urokinase-type plasminogen activator) and its inhibitor PAI-1 were used for biological risk assessment particularly for intermediate risk breast cancer patients and disease-free survival of the patients after 5 yrs of follow-up (F/U) was calculated. Material & Methods Between 2009 and 2011, 1,074 non-metastasized, primarily operated breast cancer patients from six centers in Germany were included. From 815 patients, fresh frozen tissue was obtained and processed for central testing uPA/PAI-1 by ELISA (FEMTELLE®, Sekisui Diagnostics GmbH). Low uPA/PAI-1 status is defined by uPA and PAI-1 concentrations below the published cut-offs, high status means one or both were higher than the corresponding cut-offs. Tumor characteristics were based on local pathology. The centers had to follow the national guidelines. In low-risk patients, adjuvant chemotherapy was spared. The median F/U is 56 months (range 0-78). Results In the total cohort of 1,074 patients, 166 had G1- and 237 had G3-tumors. Of the 671 patients with a G2-tumor, the following were allocated to the high-risk group: node-positive (n=371), younger than 35 yrs (n=17), and triple-negative (TN) or HER2-positive (n=118). For 253 tumors of the remaining 355 patients with an intermediate risk of recurrence (pN0, G2, HR positive, HER2-negative, ≥35 yrs), uPA/PAI-1 status was available. 126 (49.8%) were allocated to the low-risk group, one patient had a recurrence. At 5 yrs, in the total cohort 90.6% (95% CI, 89.5-91.7) of the patients were free of invasive disease. Of 114 HER2-positive tumors, 94 (82.4 %) had a high uPA/PAI-1 status, only one of the 38 HR negative/HER2 positive tumors had a low uPA/PAI-1 status. In the TN group, the majority of tumors had a high uPA/PAI-1 status (66 of 81; 81.5 %). In 30 patients lymph nodes were involved, 18.5% (n=15) had a low uPA/PAI-1 status, one event was detected. In N pos. patients with an high uPA/PAI-1 6 events were observed. Conclusion Testing for uPA/PAI-1 in the daily routine is feasible, fresh frozen tissue has been prepared from 76% of the tumors of the recruited patients, 37% of them had a low risk status. Using uPA/PAI-1, about half of the node-negative patients with an intermediate risk of recurrence were allocated to a group with an extremely low risk of recurrence and thus chemotherapy could be spared. Also in node-positive disease, uPA/PAI-1 has a prognostic impact. Citation Format: Vetter M, Hartung C, Hanf V, Lantzsch T, Uleer C, Peschel S, John J, Buchmann J, Burrig K-F, Weigert E, Thomssen C, Kantelhardt EJ. The ASCO-recommended prognostic factors uPA/PAI-1 in a multicenter cohort study (PiA) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-05-12." @default.
• W2593289896 created "2017-03-16" @default.
• W2593289896 creator A5001617286 @default.
• W2593289896 creator A5012917847 @default.
• W2593289896 creator A5017605625 @default.
• W2593289896 creator A5020142852 @default.
• W2593289896 creator A5031008665 @default.
• W2593289896 creator A5035468199 @default.
• W2593289896 creator A5045117077 @default.
• W2593289896 creator A5055148559 @default.
• W2593289896 creator A5068256625 @default.
• W2593289896 creator A5078985015 @default.
• W2593289896 creator A5082772806 @default.
• W2593289896 creator A5083715705 @default.
• W2593289896 date "2017-02-14" @default.
• W2593289896 modified "2023-09-27" @default.
• W2593289896 title "Abstract P2-05-12: The ASCO-recommended prognostic factors uPA/PAI-1 in a multicenter cohort study (PiA)" @default.
• W2593289896 doi "https://doi.org/10.1158/1538-7445.sabcs16-p2-05-12" @default.
• W2593289896 hasPublicationYear "2017" @default.
• W2593289896 type Work @default.
• W2593289896 sameAs 2593289896 @default.
• W2593289896 citedByCount "0" @default.
• W2593289896 crossrefType "proceedings-article" @default.
• W2593289896 hasAuthorship W2593289896A5001617286 @default.
• W2593289896 hasAuthorship W2593289896A5012917847 @default.
• W2593289896 hasAuthorship W2593289896A5017605625 @default.
• W2593289896 hasAuthorship W2593289896A5020142852 @default.
• W2593289896 hasAuthorship W2593289896A5031008665 @default.
• W2593289896 hasAuthorship W2593289896A5035468199 @default.
• W2593289896 hasAuthorship W2593289896A5045117077 @default.
• W2593289896 hasAuthorship W2593289896A5055148559 @default.
• W2593289896 hasAuthorship W2593289896A5068256625 @default.
• W2593289896 hasAuthorship W2593289896A5078985015 @default.
• W2593289896 hasAuthorship W2593289896A5082772806 @default.
• W2593289896 hasAuthorship W2593289896A5083715705 @default.
• W2593289896 hasConcept C121608353 @default.
• W2593289896 hasConcept C126322002 @default.
• W2593289896 hasConcept C143998085 @default.
• W2593289896 hasConcept C2776694085 @default.
• W2593289896 hasConcept C2779679481 @default.
• W2593289896 hasConcept C29456083 @default.
• W2593289896 hasConcept C530470458 @default.
• W2593289896 hasConcept C71924100 @default.
• W2593289896 hasConcept C72563966 @default.
• W2593289896 hasConceptScore W2593289896C121608353 @default.
• W2593289896 hasConceptScore W2593289896C126322002 @default.
• W2593289896 hasConceptScore W2593289896C143998085 @default.
• W2593289896 hasConceptScore W2593289896C2776694085 @default.
• W2593289896 hasConceptScore W2593289896C2779679481 @default.
• W2593289896 hasConceptScore W2593289896C29456083 @default.
• W2593289896 hasConceptScore W2593289896C530470458 @default.
• W2593289896 hasConceptScore W2593289896C71924100 @default.
• W2593289896 hasConceptScore W2593289896C72563966 @default.
• W2593289896 hasLocation W25932898961 @default.
• W2593289896 hasOpenAccess W2593289896 @default.
• W2593289896 hasPrimaryLocation W25932898961 @default.
• W2593289896 hasRelatedWork W12927781 @default.
• W2593289896 hasRelatedWork W13189666 @default.
• W2593289896 hasRelatedWork W13362822 @default.
• W2593289896 hasRelatedWork W14070955 @default.
• W2593289896 hasRelatedWork W5346711 @default.
• W2593289896 hasRelatedWork W6398642 @default.
• W2593289896 hasRelatedWork W7720014 @default.
• W2593289896 hasRelatedWork W8076426 @default.
• W2593289896 hasRelatedWork W8665794 @default.
• W2593289896 hasRelatedWork W8791024 @default.
• W2593289896 isParatext "false" @default.
• W2593289896 isRetracted "false" @default.
• W2593289896 magId "2593289896" @default.
• W2593289896 workType "article" @default.